Related Experiment Video

Updated: Sep 5, 2025

Generation and Expansion of Primary, Malignant Pleural Mesothelioma Tumor Lines
08:01

Generation and Expansion of Primary, Malignant Pleural Mesothelioma Tumor Lines

Published on: April 21, 2022

2.0K

Novel Insights Into Mesothelioma Therapy: Emerging Avenues and Future Prospects

Lukasz Kuryk1,2, Giulia Rodella2, Monika Staniszewska3

  • 1Department of Virology, National Institute of Public Health National Institute of Hygiene (NIH)-National Institute of Research, Warsaw, Poland.

Frontiers in Oncology
|July 5, 2022
PubMed

Insights

New immunotherapies, including immune checkpoint inhibitors and oncolytic adenoviruses, show promise for treating malignant mesothelioma. These advanced treatments aim to overcome tumor immunosuppression and improve patient outcomes in clinical trials.

Area of Science:

  • Oncology
  • Immunology
  • Cancer Research

Background:

  • Malignant mesothelioma is a rare, aggressive cancer primarily linked to asbestos exposure.
  • Conventional treatments offer limited efficacy for advanced stages, necessitating novel therapeutic strategies.
  • Understanding tumor-immune system interactions is crucial for developing new treatments.

Purpose of the Study:

  • To review current knowledge on novel therapeutic options for malignant mesothelioma.
  • To focus on the outcomes of recent clinical trials for mesothelioma treatment.
  • To explore the potential of immunotherapeutic approaches.

Main Methods:

  • Review of recent clinical trials and scientific literature on mesothelioma therapeutics.
  • Synthesis of data on immune checkpoint inhibitors and oncolytic adenoviruses.
  • Analysis of strategies to overcome immunosuppression in the tumor microenvironment.

Main Results:

  • Immunotherapeutic approaches, including immune checkpoint inhibitors and oncolytic adenoviruses, are emerging as promising strategies.
  • Combination therapies show potential for synergistic effects in overcoming tumor immunosuppression.
  • Clinical trials indicate a growing effort to develop more effective mesothelioma treatments.

Conclusions:

  • Novel immunotherapies represent a significant advancement in malignant mesothelioma treatment.
  • Targeting the tumor microenvironment's immunosuppressive nature is key to therapeutic success.
  • Further clinical investigation is warranted to optimize these new treatment modalities.
Keywords:
combination therapyimmune checkpoint inhibitorsimmunotherapymesotheliomaoncolytic adenoviruses

More Related Videos

Orthotopic Implantation and Peripheral Immune Cell Monitoring in the II-45 Syngeneic Rat Mesothelioma Model09:31

Orthotopic Implantation and Peripheral Immune Cell Monitoring in the II-45 Syngeneic Rat Mesothelioma Model

Published on: October 2, 2015

9.3K
Implantation and Monitoring by PET/CT of an Orthotopic Model of Human Pleural Mesothelioma in Athymic Mice07:54

Implantation and Monitoring by PET/CT of an Orthotopic Model of Human Pleural Mesothelioma in Athymic Mice

Published on: December 21, 2019

7.0K

Related Concept Videos

Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
7.8K
Cancer Therapies02:49

Cancer Therapies

Cancer therapies are various modes of treatment, such as surgery, radiation therapy, and chemotherapy that are administered to cancer patients.
However, cancer treatments can pose several challenges, as therapies used to kill cancer cells are generally also toxic to normal cells. Moreover, cancer cells mutate rapidly and can develop resistance to chemical agents or radiation therapy. Besides, all types of cancer cells may not respond to the same therapy. Some cancer cells respond to one...
7.9K
Mesenchymal Stem Cells01:19

Mesenchymal Stem Cells

Mesenchymal stem cells (MSCs) are adult stem cells that can differentiate into most connective tissue cell types, except for hematopoietic cells, depending upon the source of MSCs. For example, bone-marrow-derived MSCs (BM-MSCs) can differentiate into osteocytes, hepatocytes, and pancreatic and neuronal cells. MSCs can be isolated from various sources such as bone marrow, placenta, adipose tissue, teeth, and Wharton’s jelly, a gelatinous substance in the umbilical cord. The ease of their...
5.0K
Tumor Immunotherapy01:27

Tumor Immunotherapy

Immunotherapy is a treatment that boosts or manipulates the immune system to fight diseases, including cancer. For instance, by stimulating an immune response through vaccinations against viruses that cause cancers, like hepatitis B virus and human papillomavirus, these diseases can be prevented. Nonetheless, some cancer cells can avoid the immune system due to their rapid mutation and division. The immune response to many cancers involves three phases: elimination, equilibrium, and escape.
652
Combination Therapies and Personalized Medicine02:50

Combination Therapies and Personalized Medicine

Combining two or more treatment methods increases the life span of cancer patients while reducing damage to vital organs or tissue from the overuse of a single treatment. Combination therapy also targets different cancer-inducing pathways, thus reducing the chances of developing resistance to treatment.
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
5.1K
Treatment Resistant Cancers02:56

Treatment Resistant Cancers

Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...
3.4K